SUPERNUS PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: Georges Gemayel, Ph.D.

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Georges Gemayel, Ph.D”): 48,410,580 for, 2,121,505 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 98 asset managers below reported 26,214,022 for, 874,729 withheld, 1,822 unknown.

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

Description as filed by funds: to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: Bethany L. Sensenig

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bethany L. Sensenig”): 48,568,282 for, 1,963,803 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 97 asset managers below reported 26,469,869 for, 609,162 withheld, 1,822 unknown.

Showing the 25 largest of 97 asset managers. See all 97 in the interactive database.

Description as filed by funds: to consider and act upon a proposal to amend the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan to increase the number of shares available under the plan and make certain technical updates; and

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“4. To act upon a proposal to amend the Supernus Pharmaceuticals, Inc”): 45,522,166 for, 4,972,675 against, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 25,157,250 for, 1,874,752 against, 17,193 abstained, 1,822 unknown.

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

Description as filed by funds: to approve, on a non-binding basis, the compensation paid to our named executive officers;

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“2. To approve, on a non-binding basis, the compensation paid to our named executive officers”): 48,217,539 for, 2,290,237 against, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of SUPERNUS PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (3 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 97 managers: 26,756,528 for, 275,344 against, 17,193 abstained, 1,822 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 227 managers: 27,131,988 for, 1,693,971 against, 12,633 not voted, 2,684 unknown. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“3. Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2024”): 52,182,042 for, 272,906 against, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 98 asset managers below reported 27,071,482 for, 76 against, 17,193 abstained, 1,822 unknown.

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.